Citadel Advisors’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-19,900
| Closed | -$179K | – | 8446 |
|
|
2016
Q3 | $179K | Buy |
19,900
+5,900
| +42% | +$42K | ﹤0.01% | 6376 |
|
|
2016
Q2 | $75K | Buy |
+14,000
| New | +$71.8K | ﹤0.01% | 6306 |
|
|
2016
Q1 | – | Sell |
-18,700
| Closed | -$97K | – | 9315 |
|
|
2015
Q4 | $97K | Sell |
18,700
-25,400
| -58% | -$147K | ﹤0.01% | 6735 |
|
|
2015
Q3 | $267K | Sell |
44,100
-50,800
| -54% | -$623K | ﹤0.01% | 5737 |
|
|
2015
Q2 | $1.5M | Buy |
94,900
+37,900
| +66% | +$460K | ﹤0.01% | 3419 |
|
|
2015
Q1 | $620K | Buy |
57,000
+33,900
| +147% | +$346K | ﹤0.01% | 4604 |
|
|
2014
Q4 | $243K | Buy |
23,100
+13,400
| +138% | +$131K | ﹤0.01% | 5737 |
|
|
2014
Q3 | $93K | Sell |
9,700
-2,400
| -20% | -$24.5K | ﹤0.01% | 6476 |
|
|
2014
Q2 | $140K | Sell |
12,100
-18,700
| -61% | -$170K | ﹤0.01% | 5929 |
|
|
2014
Q1 | $308K | Sell |
30,800
-2,200
| -7% | -$31.8K | ﹤0.01% | 4985 |
|
|
2013
Q4 | $430K | Buy |
33,000
+30,100
| +1,038% | +$415K | ﹤0.01% | 4197 |
|
|
2013
Q3 | $43K | Buy |
2,900
+800
| +38% | +$9.59K | ﹤0.01% | 5883 |
|
|
2013
Q2 | $20K | Buy |
+2,100
| New | +$14.2K | ﹤0.01% | 6078 |
|
Citadel Advisors's RPTP Position: Q3 2016 in Review
Citadel Advisors sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q3 2016, closing a stake of 31,894 shares — an estimated $227K sold.
Citadel Advisors first reported a position in RPTP in Q2 2013 and held it in 11 quarters. The position peaked at $3.53M in Q2 2015. 111 funds tracked by Wall St. Rank hold RPTP as of Q3 2016.
- Citadel Advisors reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Citadel Advisors sold 31,894 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q3 2016, an estimated $227K.
- Citadel Advisors first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 11 quarters.
- Citadel Advisors's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $3.53M in Q2 2015.
- 111 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q3 2016.
Based on Citadel Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.